Enanta Pharmaceuticals (ENTA) Enterprise Value (2012 - 2026)

Enanta Pharmaceuticals has reported Enterprise Value for 15 years, with the latest figure at -$163.8 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value rose 15.31% year-over-year to -$163.8 million; the trailing twelve-month figure through Mar 2026 stood at -$163.8 million (up 15.31% YoY), and the FY2025 full-year result was -$188.9 million, up 23.9% from the prior year.
• Enterprise Value for Q1 2026 stood at -$163.8 million, up from -$185.8 million in the prior quarter.
• The five-year high for Enterprise Value was -$85.4 million in Q3 2023, with the low at -$386.6 million in Q2 2023.
• Historically, Enterprise Value has averaged -$232.2 million across 5 years, with a median of -$216.7 million in 2024.
• Annual changes were most pronounced in 2023 — Enterprise Value soared 65.74% — and 2024, when it tumbled 190.66%.
• Enanta Pharmaceuticals' Enterprise Value stood at -$214.5 million in 2022, then sank by 57.2% to -$337.2 million in 2023, then jumped by 35.73% to -$216.7 million in 2024, then gained by 14.23% to -$185.8 million in 2025, then rose by 11.88% to -$163.8 million in 2026.
• The last three Enterprise Value figures came in at -$163.8 million (Q1 2026), -$185.8 million (Q4 2025), and -$188.9 million (Q3 2025), per Business Quant data.